logo-loader
viewOpen Orphan Plc

Open Orphan partnership with Ipsen Group 'already delivering substantial revenues'

Open Orphan Plc's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after announcing plans to make its Venn Life Sciences business profitable by way of a three-year preferred partnership agreement with French pharma company Ipsen Group.

Friel says the deal is the first of many steps to make Venn profitable and deliver a re-rating of the business.

Quick facts: Open Orphan Plc

Price: 5.775 GBX

AIM:ORPH
Market: AIM
Market Cap: £14.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan Plc named herein, including the promotion by the Company of Open Orphan Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan 'continuing to target rapid scale-up and profitability'

Proactive Research analyst Emma Ulker says Open Orphan (LON:ORPH) is continuing to target rapid scale-up and profitability in the dynamic European orphan and rare disease consulting sector via acquisitions and organic means. The company’s Venn Life Sciences consulting arm has recently signed...

2 days, 22 hours ago

2 min read